Landmark Phase 3 Study of Xarelto Plus Aspirin Shows Significant Benefit in Patients with Symptomatic PAD after Lower-Extremity Revascularization - PharmaLive

Landmark Phase 3 Study of Xarelto Plus Aspirin Shows Significant Benefit in Patients with Symptomatic PAD after Lower-Extremity Revascularization  PharmaLive

Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more